U.S. markets closed

Oncolytics Biotech Inc. (ONCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.0100-0.6300 (-13.58%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.6400
Open4.7400
Bid3.9300 x 1400
Ask4.0100 x 1400
Day's Range3.8400 - 4.7400
52 Week Range1.2800 - 4.8300
Volume3,564,218
Avg. Volume2,088,741
Market Cap209.574M
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Oncolytics Biotech (ONCY) Enters Overbought Territory
    Zacks

    Oncolytics Biotech (ONCY) Enters Overbought Territory

    Oncolytics Biotech (ONCY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

  • 2 “Strong Buy” Penny Stocks With Massive Upside Ahead
    TipRanks

    2 “Strong Buy” Penny Stocks With Massive Upside Ahead

    Does high risk mean high reward? Not necessarily, so say the pros on Wall Street. Specifically citing penny stocks, or stocks that trade for less than $5 per share, analysts advise caution as these names might still be in the early innings, or it could be that they face an uphill battle that is just too steep. Luring investors with their bargain price tags, these stocks might be up against overpowering headwinds or have weak fundamentals. However, analysts argue there are early-stage companies that reflect promising opportunities, with the low share prices meaning you get significantly more bang for your buck. What’s more, even what seems like minor share price appreciation can result in massive percentage gains. The bottom line? Not all risk is created equal. To this end, the pros recommend doing some due diligence before making an investment decision. Using TipRanks’ database, we pulled two penny stocks that have earned a “Strong Buy” consensus rating from the analyst community. Not to mention each offers up massive upside potential. Oncolytics Biotech (ONCY) We'll start with Oncolytics, a biotechnology company focused on the use of immunotherapy combinations as treatments for cancer. The company’s approach uses pelareorep, an immune-oncolytic virus, to deliver therapeutic agents that both directly target the tumor and activate the immune system’s natural defenses. Oncolytics is conducting its various research programs in partnership with several of the big names in biotech, including Pfizer, Merck, Roche, and Bristol-Myers Squibb. The company’s development pipeline is testing the compatibility of pelareorep in conjunction with the larger companies’ anti-cancer drugs. To date, pelareorep demonstrated positive results making early-stage breast cancer tumors more amenable to checkpoint inhibitor therapy. The data showed that pelareorep induced a robust anti-tumor immune response in some types of breast cancer. There are three ongoing clinical programs in place relating to breast cancer: The company's Phase 2 AWARE-1 study, combining pelareorep with Roche’s anti-PD-L1 mAb Tecentriq, is assessing the impact of the combination on early-stage breast cancer response rate and overall survival. Meanwhile, the BRACELET-1 Phase 2 study will evaluate efficacy of pelareorep in combination with Pfizer’s anti-PD-L1 mAb Bavencio in breast cancer. A third Phase 2 breast cancer trial, IRENE, will evaluate pelareorep's ability to improve outcomes in triple-negative breast cancer. The study is assessing pelareorep's safety and efficacy in combination with retifanlimab. ONCY strong pipeline and $3.01 share price have scored it substantial praise from the pros on Wall Street. H.C. Wainwright analyst Patrick Trucchio conducted a deep dive into Oncolytics, and concluded that the company offers a sound investment opportunity. “Oncolytics' lead compound, pelareorep (pela)… is on the cusp of demonstrating potential to upend the treatment paradigms of several cancers, in our view... We believe it is the studies being conducted in breast cancer (BrCa) that could generate substantial value for shareholders in 2021 and beyond,” Trucchio opined. The analyst added, "Since the approval of the first OV T-VEC in 2015, there have been at least eight licensing or acquisition deal announcements, including the $394M acquisition of Viralytics by Merck in February 2018 and the €210M acquisition of ViraTherapeutics by Boehringer Ingelheim in September 2018. Oncolytics has collaboration, supply agreements, and combination arrangements with many major biopharmaceutical companies and organizations involved in cancer research... Positive data readouts in any or all of the plethora of combination trials underway with pela and ICI could catalyze a much higher valuation than the recent M&A, in our view." To this end, Trucchio rates ONCY a Buy, and his $15 price target implies a robust one-year upside potential of ~397%. (To watch Trucchio’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that ONCY is a Strong Buy. Given its $8.51 average price target, upside of ~182% could be in store for investors. (See ONCY stock analysis on TipRanks) Xeris Pharmaceuticals (XERS) Sticking with the biotech sector, let’s take a look at Xeris Pharmaceuticals. This company has one important advantage over many of its peers: it has a drug on the market, approved for use. Gvoke, its self-administered glucagon injection device, was approved by the FDA in September 2019 for use by adults and kids suffering severe low blood sugar (hypoglycemia) due to diabetes. The product has been generating revenues for Xeris for the past 5 quarters, and in 2H20 those revenues began to ramp up. In the company’s most recent quarterly report, for 4Q20, Xeris showed an 11% sequential increase in Gvoke prescriptions and quarterly sales of $7.1 million; full-year sales of the self-injection device totaled $20.2 million. The company also received, in December 2020, a positive opinion from the European Medicine Agency on Oglou, the room-stable liquid glucagon used in Gvoke, as well as European Commission authorization for marketing starting in February 2021. Xeris is targeting 4Q21 to launch Oglou in the European Union. The company is not resting on its Gvoke laurels. It has an active development pipeline, with several additional self-administered glucagon devices, as well as additional drug candidates in development for the treatment of diabetes and epilepsy. Analyst Difei Yang, writing from Mizuho, sees Gvoke as the key to Xeris’ path forward. “Gvoke continued to gain market share in the quarter (we estimate recent weekly share at ~16%) from legacy glucagon kits, but we note that the total glucagon market growth rate has stagnated as a result of Covid-19. We forecast a re-acceleration of the glucagon market in 2H21 as Covid-19 abates, and expect Gvoke fundamentals to improve when the market growth rate picks up,” Yang wrote. Along with those comments, the analyst put a Buy rating on XERS shares, and a $14 price target that indicates room for 225% growth over the coming year. (To watch Yang’s track record, click here) This is another stock that Wall Street likes, as shown by the unanimous Strong Buy consensus rating derived from 3 recent positive reviews. Xeris shares are selling for $4.30 right now, and their $10.67 average price target implies an upside of ~148% in 2021. (See XERS stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Benzinga

    Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2021

    Upgrades For CVR Energy Inc (NYSE:CVI), Credit Suisse upgraded the previous rating of Underperform to Neutral. In the third quarter, CVR Energy showed an EPS of $0.57, compared to $1.18 from the year-ago quarter. At the moment, the stock has a 52-week-high of $35.63 and a 52-week-low of $9.81. CVR Energy closed at $21.13 at the end of the last trading period. Credit Suisse upgraded the previous rating for Par Pacific Holdings Inc (NYSE:PARR) from Underperform to Neutral. In the third quarter, Par Pacific Hldgs showed an EPS of $1.06, compared to $0.13 from the year-ago quarter. The stock has a 52-week-high of $20.43 and a 52-week-low of $5.72. At the end of the last trading period, Par Pacific Hldgs closed at $15.40. RBC Capital upgraded the previous rating for Bausch Health Companies Inc (NYSE:BHC) from Sector Perform to Outperform. In the third quarter, Bausch Health Cos showed an EPS of $1.32, compared to $1.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $32.25 and a 52-week-low of $11.15. Bausch Health Cos closed at $31.48 at the end of the last trading period. For Black Knight Inc (NYSE:BKI), Susquehanna upgraded the previous rating of Neutral to Positive. Black Knight earned $0.60 in the fourth quarter, compared to $0.54 in the year-ago quarter. The current stock performance of Black Knight shows a 52-week-high of $97.19 and a 52-week-low of $50.01. Moreover, at the end of the last trading period, the closing price was at $82.05. For Anterix Inc (NASDAQ:ATEX), JP Morgan upgraded the previous rating of Neutral to Overweight. At the moment, the stock has a 52-week-high of $57.75 and a 52-week-low of $27.27. Anterix closed at $40.55 at the end of the last trading period. According to Jefferies, the prior rating for Oshkosh Corp (NYSE:OSK) was changed from Hold to Buy. In the first quarter, Oshkosh showed an EPS of $1.13, compared to $1.10 from the year-ago quarter. The stock has a 52-week-high of $100.77 and a 52-week-low of $46.72. At the end of the last trading period, Oshkosh closed at $99.14. For Palantir Technologies Inc (NYSE:PLTR), Goldman Sachs upgraded the previous rating of Neutral to Buy. In the fourth quarter, Palantir Technologies earned $0.06. The current stock performance of Palantir Technologies shows a 52-week-high of $45.00 and a 52-week-low of $8.90. Moreover, at the end of the last trading period, the closing price was at $27.84. KeyBanc upgraded the previous rating for Rexnord Corp (NYSE:RXN) from Sector Weight to Overweight. In the third quarter, Rexnord showed an EPS of $0.39, compared to $0.48 from the year-ago quarter. The current stock performance of Rexnord shows a 52-week-high of $49.08 and a 52-week-low of $18.87. Moreover, at the end of the last trading period, the closing price was at $45.11. According to KeyBanc, the prior rating for Regal Beloit Corp (NYSE:RBC) was changed from Sector Weight to Overweight. For the fourth quarter, Regal Beloit had an EPS of $1.78, compared to year-ago quarter EPS of $1.25. The current stock performance of Regal Beloit shows a 52-week-high of $146.97 and a 52-week-low of $51.99. Moreover, at the end of the last trading period, the closing price was at $133.19. See all analyst ratings upgrades. Downgrades Truist Securities downgraded the previous rating for KAR Auction Services Inc (NYSE:KAR) from Buy to Hold. For the fourth quarter, KAR Auction Services had an EPS of $0.01, compared to year-ago quarter EPS of $0.19. The current stock performance of KAR Auction Services shows a 52-week-high of $23.53 and a 52-week-low of $9.41. Moreover, at the end of the last trading period, the closing price was at $18.45. Roth Capital downgraded the previous rating for Kodiak Sciences Inc (NASDAQ:KOD) from Buy to Neutral. In the third quarter, Kodiak Sciences showed an EPS of $0.80, compared to $0.33 from the year-ago quarter. At the moment, the stock has a 52-week-high of $171.21 and a 52-week-low of $35.49. Kodiak Sciences closed at $145.58 at the end of the last trading period. For KAR Auction Services Inc (NYSE:KAR), Guggenheim downgraded the previous rating of Neutral to Sell. KAR Auction Services earned $0.01 in the fourth quarter, compared to $0.19 in the year-ago quarter. At the moment, the stock has a 52-week-high of $23.53 and a 52-week-low of $9.41. KAR Auction Services closed at $18.45 at the end of the last trading period. For Palantir Technologies Inc (NYSE:PLTR), William Blair downgraded the previous rating of Market Perform to Underperform. Palantir Technologies earned $0.06 in the fourth quarter. The stock has a 52-week-high of $45.00 and a 52-week-low of $8.90. At the end of the last trading period, Palantir Technologies closed at $27.84. Morgan Stanley downgraded the previous rating for Fortive Corp (NYSE:FTV) from Overweight to Equal-Weight. For the fourth quarter, Fortive had an EPS of $0.70, compared to year-ago quarter EPS of $1.03. At the moment, the stock has a 52-week-high of $82.12 and a 52-week-low of $37.31. Fortive closed at $69.85 at the end of the last trading period. For Cortexyme Inc (NASDAQ:CRTX), Jefferies downgraded the previous rating of Buy to Hold. In the third quarter, Cortexyme showed an EPS of $0.73, compared to $0.37 from the year-ago quarter. The current stock performance of Cortexyme shows a 52-week-high of $73.84 and a 52-week-low of $26.66. Moreover, at the end of the last trading period, the closing price was at $30.72. JP Morgan downgraded the previous rating for bluebird bio Inc (NASDAQ:BLUE) from Overweight to Neutral. For the third quarter, bluebird bio had an EPS of $2.94, compared to year-ago quarter EPS of $3.73. The stock has a 52-week-high of $90.63 and a 52-week-low of $26.11. At the end of the last trading period, bluebird bio closed at $28.44. See all analyst ratings downgrades. Initiations With an Overweight rating, Wells Fargo initiated coverage on Chesapeake Energy Corp (NASDAQ:CHK). The price target seems to have been set at $54.00 for Chesapeake Energy. The current stock performance of Chesapeake Energy shows a 52-week-high of $77.50 and a 52-week-low of $0.12. Moreover, at the end of the last trading period, the closing price was at $43.55. Roth Capital initiated coverage on DiaMedica Therapeutics Inc (NASDAQ:DMAC) with a Buy rating. The price target for DiaMedica Therapeutics is set to $38.00. For the third quarter, DiaMedica Therapeutics had an EPS of $0.19, compared to year-ago quarter EPS of $0.20. The current stock performance of DiaMedica Therapeutics shows a 52-week-high of $10.88 and a 52-week-low of $1.87. Moreover, at the end of the last trading period, the closing price was at $9.40. Needham initiated coverage on Cormedix Inc (NASDAQ:CRMD) with a Buy rating. The price target for Cormedix is set to $31.00. The stock has a 52-week-high of $17.14 and a 52-week-low of $2.16. At the end of the last trading period, Cormedix closed at $13.99. With an Outperform rating, BMO Capital initiated coverage on Phathom Pharmaceuticals Inc (NASDAQ:PHAT). The price target seems to have been set at $63.00 for Phathom Pharmaceuticals. Phathom Pharmaceuticals earned $1.02 in the third quarter, compared to $1.07 in the year-ago quarter. The stock has a 52-week-high of $64.54 and a 52-week-low of $22.06. At the end of the last trading period, Phathom Pharmaceuticals closed at $42.80. With an Overweight rating, Barclays initiated coverage on IDEXX Laboratories Inc (NASDAQ:IDXX). The price target seems to have been set at $600.00 for IDEXX Laboratories. IDEXX Laboratories earned $1.76 in the fourth quarter, compared to $1.04 in the year-ago quarter. The current stock performance of IDEXX Laboratories shows a 52-week-high of $548.58 and a 52-week-low of $168.65. Moreover, at the end of the last trading period, the closing price was at $538.16. With an Overweight rating, Barclays initiated coverage on Covetrus Inc (NASDAQ:CVET). The price target seems to have been set at $48.00 for Covetrus. For the third quarter, Covetrus had an EPS of $0.26, compared to year-ago quarter EPS of $0.17. The stock has a 52-week-high of $40.77 and a 52-week-low of $4.04. At the end of the last trading period, Covetrus closed at $37.58. With a Buy rating, DA Davidson initiated coverage on First Citizens BancShares Inc (NASDAQ:FCNCA). The price target seems to have been set at $875.00 for First Citizens BancShares. First Citizens BancShares earned $13.59 in the fourth quarter, compared to $9.55 in the year-ago quarter. The current stock performance of First Citizens BancShares shows a 52-week-high of $749.50 and a 52-week-low of $276.08. Moreover, at the end of the last trading period, the closing price was at $746.00. With a Buy rating, HC Wainwright & Co. initiated coverage on Oncolytics Biotech Inc (NASDAQ:ONCY). The price target seems to have been set at $15.00 for Oncolytics Biotech. For the third quarter, Oncolytics Biotech had an EPS of $0.12, compared to year-ago quarter EPS of $0.16. The stock has a 52-week-high of $4.19 and a 52-week-low of $0.94. At the end of the last trading period, Oncolytics Biotech closed at $3.01. Goldman Sachs initiated coverage on Patria Investments Ltd (NASDAQ:PAX) with a Buy rating. The price target for Patria Investments is set to $28.00. The stock has a 52-week-high of $23.28 and a 52-week-low of $17.23. At the end of the last trading period, Patria Investments closed at $22.38. With a Buy rating, BTIG initiated coverage on Vuzix Corporation (NASDAQ:VUZI). The price target seems to have been set at $30.00 for Vuzix. For the third quarter, Vuzix had an EPS of $0.13, compared to year-ago quarter EPS of $0.18. The current stock performance of Vuzix shows a 52-week-high of $17.36 and a 52-week-low of $0.86. Moreover, at the end of the last trading period, the closing price was at $17.16. KeyBanc initiated coverage on Howmet Aerospace Inc (NYSE:HWM) with an Overweight rating. The price target for Howmet Aerospace is set to $36.00. For the fourth quarter, Howmet Aerospace had an EPS of $0.21, compared to year-ago quarter EPS of $0.53. The stock has a 52-week-high of $29.10 and a 52-week-low of $9.87. At the end of the last trading period, Howmet Aerospace closed at $28.37. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaEarnings Preview: GlobantEarnings Preview for OPKO Health© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.